Dr. Gao Jimin, PhD

Position: Professor of Clinical Immunology; Doctoral and Post-doctoral supervisor

Institution: Wenzhou Medical University

Biography

Dr. Gao Jimin is a Leading Talent in Zhejiang Province and a Qianjiang-endowed Professor at Wenzhou Medical University. He holds a Bachelor's and Master's degree from the First Military Medical University (1986 and 1989) and a Ph.D. from the Fourth Military Medical University (1994). His primary research focuses on the pathogenesis, immunological diagnosis, and treatment of inflammation-related diseases, such as tumors. He has won several prestigious awards, including the first prize of the Zhejiang Provincial Science and Technology Award and the second prize of the PLA Science and Technology Progress Award.

Dr. Gao has led nine national scientific research projects and published over 148 SCI papers, including in journals like Science, with 88 of them as the (co-)corresponding author. He holds 28 patents, 10 of which have been granted. He was awarded the first prize of the Zhejiang Science and Technology Award in 2013 for his project on the "Cell surface-modified tumor cell vaccine". Dr. Gao also developed the recombinant human G-CSF injection, which received national approval in 1998 and generated over 100 million yuan in profits by 2010. He has contributed to several academic textbooks and overseen national-level courses in immunology and clinical immunological testing.

His recent research focuses on CAR-T, CAR-NK, Hi-TCR-T therapies, and tumor cell vaccines immobilized on the surface of tumor cell membranes. His work spans the development of lentiviral preparation processes, immune cell expansion, and clinical trials, placing his group at the forefront of global immune cell therapy research.

Research Interests

· Pathogenesis, immunology, and treatment of inflammation-related diseases (including tumors)

· Development of CAR-T, CAR-NK, Hi-TCR-T, and cell membrane-modified tumor vaccines

· Lentiviral preparation process and immune cell expansion

· Clinical trials in immune cell therapies

Awards and Recognition

· First Prize, Zhejiang Provincial Science and Technology Award (2013)

· Second Prize, PLA Science and Technology Progress Award

· Second Prize, Guangdong Provincial Science and Technology Progress Award

· National Natural Science Foundation of China Projects: Nine major projects

· Developed Recombinant Human G-CSF Injection, National II-class New Drug Certificate (1998)

· Profits exceeding 100 million yuan from G-CSF injection by 2010

Education

· Bachelor's and Master's in Medicine, First Military Medical University (1986, 1989)

· Doctorate in Medicine, Fourth Military Medical University (1994)

Professional Affiliations

· Chief Editor, Two academic textbooks

· Deputy Chief Editor, Three academic textbooks

· Chief Instructor, National Excellent Course "Immunology and Immunological Testing"

· Chief Instructor, National Resource Sharing Course "Clinical Immunological Testing"

Grants and Research

· Principal Investigator, Nine National-Level Scientific Research Projects

· National Natural Science Foundation of China: Key Programs and Surface Projects

Selected Publications

· Ming Liu et al. WAVE2 suppresses mTOR activation to maintain T cell homeostasis and prevent autoimmunity. Science 2021

· Wei C, Xu T, Duan D, et al，1493 The armoured T-cell antigen coupler receptor (TAC) T cells with the integrated CD28 signaling, TAC28-T, Journal for ImmunoTherapy of Cancer (2024)

· Yang Fang, Yan-jing Wang , Hong-li Zhao , Xin Huang , Yi-nan Fang , Wen-yi Chen , Ruo-zhen Han , Ai Zhao , Ji-min Gao. Development of FAP-Targeted Chimeric Antigen Receptor NK-92 Cells for Non-Small Cell Lung Cancer. Discovery Medicine. 2023